<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868567</url>
  </required_header>
  <id_info>
    <org_study_id>2016-247</org_study_id>
    <nct_id>NCT02868567</nct_id>
  </id_info>
  <brief_title>Use of Dalfampridine in Primary Lateral Sclerosis</brief_title>
  <official_title>A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will comprise an 18-week open label safety and tolerability trial. In this study,&#xD;
      a total of 35 subjects with primary lateral sclerosis PLS or upper motor neuron predominate&#xD;
      ALS will be enrolled. At the initial screening evaluation, a baseline T25FW will be obtained.&#xD;
      This baseline test will be repeated at weeks 2, 4, 6, 10, 14 18. The validity of this measure&#xD;
      was shown in MS studies when compared to the MSWS-12 (12 item walking scale) and CGI&#xD;
      (clinical global impression) scales (35-37). A consistent responder will be defined as&#xD;
      improvement in 3 of 4 Timed 25Foot Walk while on medication, compared with the baseline&#xD;
      results while off medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>consistent improvement in the Timed 25 Foot Walk test</measure>
    <time_frame>over the duration of the study at week 2, 4, 6, 10, 14, 18</time_frame>
    <description>speed of walking 25 feet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Dalfampridine on quality of life</measure>
    <time_frame>over the course of study at weeks 2, 4, 6, 10, 14, 18</time_frame>
    <description>ALSFRS-R,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Dalfampridine on functional status</measure>
    <time_frame>over the course of study at weeks 2, 4, 6, 10, 14, 18</time_frame>
    <description>MSWS-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Dalfampridine on functional status</measure>
    <time_frame>over the course of study at weeks 2, 4, 6, 10, 14, 18</time_frame>
    <description>CGI, SGI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Dalfampridine on functional status</measure>
    <time_frame>over the course of study at weeks 2, 4, 6, 10, 14, 18</time_frame>
    <description>2MW, TUG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Dalfampridine on functional status</measure>
    <time_frame>over the course of study at weeks 2, 4, 6, 10, 14, 18</time_frame>
    <description>PPT, Hand and Foot tapping.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Motor Neuron Disease, Upper</condition>
  <arm_group>
    <arm_group_label>Ampyra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ampyra open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalfampridine</intervention_name>
    <description>Pill open label</description>
    <arm_group_label>Ampyra</arm_group_label>
    <other_name>ampyra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged 18-99;&#xD;
&#xD;
          2. Diagnosis of upper motor neuron disease, compatible with PLS but may include upper&#xD;
             motor neuron (UMN) predominant ALS, defined as only upper motor neuron (UMN) features&#xD;
             in at least 2 body regions on examination.&#xD;
&#xD;
          3. EMG within 3 months of enrollment with minimal or no evidence of lower motor neuron&#xD;
             disease,&#xD;
&#xD;
          4. Time from symptom onset &gt; 18 months&#xD;
&#xD;
          5. No previous allergy to dalfampridine&#xD;
&#xD;
          6. No current or exposure to any therapeutic agent targeting PLS or ALS within 30 days of&#xD;
             enrollment.&#xD;
&#xD;
          7. Must have a forced vital capacity (FVC) ≥ 60% of expected&#xD;
&#xD;
          8. Written informed consent prior to screening is present.&#xD;
&#xD;
          9. Subjects on a stable dose of or have not taken Riluzole for at least thirty days&#xD;
&#xD;
         10. Impaired walking as measured by a Hauser Index of greater than 1 and less than 7 (2 to&#xD;
             6, inclusive);&#xD;
&#xD;
         11. Mini Mental Status Score &gt; 22 and deemed by the PI of being capable of providing&#xD;
             informed consent and following trial procedures.&#xD;
&#xD;
         12. Geographically accessible to the site.&#xD;
&#xD;
         13. Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile,&#xD;
             or using adequate birth control methods) for the duration of the study and three&#xD;
             months after study completion. Adequate contraception includes: abstinence, hormonal&#xD;
             contraception (oral contraception, implanted contraception, injected contraception or&#xD;
             other hormonal contraception, for example patch or contraceptive ring), intrauterine&#xD;
             device (IUD) in place for ≥ 3 months, barrier method in conjunction with spermicide,&#xD;
             or another adequate method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically significant liver disease, renal disease, peripheral neuropathy,&#xD;
             serious peripheral vascular disease, known HSP or + C9orf72 or SPG4 mutation, or any&#xD;
             other medical condition felt to be exclusionary by the investigator;&#xD;
&#xD;
          2. Unwillingness to sign informed consent or any other reasons for which the investigator&#xD;
             feels the subject cannot complete the study;&#xD;
&#xD;
          3. Women who are pregnant, breastfeeding, or trying to become pregnant;&#xD;
&#xD;
          4. Active cancer within the previous 2 years, except treated basal cell carcinoma of the&#xD;
             skin;&#xD;
&#xD;
          5. Subjects taking any other experimental drugs within 30 days prior to enrollment;&#xD;
&#xD;
          6. Patient has any history of seizures; brain surgery, brain implants, any metallic&#xD;
             implants above the neck, cardiac pacemakers, cochlear implants, piercing or body&#xD;
             modification above the neck, known history of TMS related complications or&#xD;
             side-effects, tinnitus.&#xD;
&#xD;
          7. Patient has moderate or severe renal impairment as defined by a calculated creatinine&#xD;
             clearance of ≤50 mL/minute;&#xD;
&#xD;
          8. Patient has been administered botulinum toxin in the lower extremities within 6 months&#xD;
             prior to the screening visit and/or is expected to receive botulinum toxin in the&#xD;
             lower extremities during the course of the study;&#xD;
&#xD;
          9. Patient has a known allergy to pyridine-containing substances or any of the inactive&#xD;
             ingredients of the dalfampridine tablet (colloidal silicon dioxide, hydroxypropyl&#xD;
             methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol,&#xD;
             and titanium dioxide);&#xD;
&#xD;
         10. Patient has a history of drug or alcohol abuse within the past year;&#xD;
&#xD;
         11. Patient has clinically significant abnormal laboratory values.&#xD;
&#xD;
         12. Anything else that, in the opinion of the SI, would place the subject at increased&#xD;
             risk or preclude the subject's full compliance with or completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dale Lange, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HSS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mona Shahbazi, NP</last_name>
    <phone>2127742361</phone>
    <phone_ext>6467978917</phone_ext>
    <email>shahbazim@hss.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shara Holzberg, MS</last_name>
    <phone>6467978592</phone>
    <phone_ext>6467978917</phone_ext>
    <email>holzbergs@hss.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida Gainsville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Magenheim</last_name>
      <phone>352-733-2430</phone>
      <email>jessica.magenheim@neurology.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Steshyn</last_name>
      <phone>352-733-2434</phone>
      <email>jennifer.steshyn@neurology.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jim Wymer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Yerton</last_name>
      <phone>617-724-7398</phone>
      <email>myerton@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sabrina Paganoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Shahbazi, NP</last_name>
      <phone>212-774-2361</phone>
      <email>shahbazim@hss.edu</email>
    </contact>
    <investigator>
      <last_name>Dale J Lange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

